Monthly Prescribing Reference

Positive Results for Oral Tofacitinib in Ulcerative Colitis Presented

Pfizer announced detailed results from the first 2 pivotal Phase 3 trials of the OCTAVE program evaluating oral tofacitinib 10mg twice daily in inducing remission in adults with moderately to severely ...
Nasdaq

Sierra Wireless Octave Wins “IoT Innovation of the Year” Award in 2020 Mobile Breakthrough Award Program

Annual Awards Program Recognizes Top Mobile and Wireless Companies and Solutions Around the Globe Sierra Wireless’ Octave is an all-in-one edge-to-cloud solution for Industrial IoT (IIoT) that enables ...
Business Wire

Pfizer Announces Oral Tofacitinib, an Investigational JAK Inhibitor, Meets Primary and Key Secondary Endpoints in Two Pivotal Phase 3 Ulcerative Colitis Trials

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ...
Yahoo Finance

Celgene & Pfizer Present Data from Ulcerative Colitis Trials

Last week, a number of biotech companies presented data from their studies on ulcerative colitis (UC) at the annual meeting of the Congress of the European Crohn's and Colitis Organisation (ECCO). Two ...
Business Wire

Sierra Wireless Octave Wins “IoT Innovation of the Year” Award in 2020 Mobile Breakthrough Award Program

VANCOUVER, British Columbia--(BUSINESS WIRE)--Sierra Wireless (NASDAQ: SWIR) (TSX: SW), the leading IoT solutions provider that combines devices, network services and software to unlock value in the ...